Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.
Nicolás D, Ambrosioni J, Sued O, Brunet M, López-Diéguez M, Manzardo C, Agüero F, Tuset M, Plana M, Guardo AC, Mosquera MM, Muñoz-Fernández MÁ, Caballero M, Marcos MÁ, Gatell JM, de Lazzari E, Gallart T, Miró JM. Nicolás D, et al. Among authors: ambrosioni j. J Antimicrob Chemother. 2017 Mar 1;72(3):829-836. doi: 10.1093/jac/dkw462. J Antimicrob Chemother. 2017. PMID: 27999018 Clinical Trial.
HIV treatment for prevention.
Ambrosioni J, Calmy A, Hirschel B. Ambrosioni J, et al. J Int AIDS Soc. 2011 May 25;14:28. doi: 10.1186/1758-2652-14-28. J Int AIDS Soc. 2011. PMID: 21612619 Free PMC article. Review.
Update on antiretroviral treatment during primary HIV infection.
Ambrosioni J, Nicolas D, Sued O, Agüero F, Manzardo C, Miro JM. Ambrosioni J, et al. Expert Rev Anti Infect Ther. 2014 Jul;12(7):793-807. doi: 10.1586/14787210.2014.913981. Epub 2014 May 7. Expert Rev Anti Infect Ther. 2014. PMID: 24803105 Review.
Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012).
Ambrosioni J, Sued O, Nicolas D, Parera M, López-Diéguez M, Romero A, Agüero F, Marcos MÁ, Manzardo C, Zamora L, Gómez-Carrillo M, Gatell JM, Pumarola T, Miró JM. Ambrosioni J, et al. PLoS One. 2015 Jun 3;10(6):e0125837. doi: 10.1371/journal.pone.0125837. eCollection 2015. PLoS One. 2015. PMID: 26039689 Free PMC article.
Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.
Sued O, Ambrosioni J, Nicolás D, Manzardo C, Agüero F, Claramonte X, Plana M, Tuset M, Pumarola T, Gallart T, Gatell JM, Miró JM. Sued O, et al. Among authors: ambrosioni j. PLoS One. 2015 Jul 17;10(7):e0131651. doi: 10.1371/journal.pone.0131651. eCollection 2015. PLoS One. 2015. PMID: 26186440 Free PMC article. Clinical Trial.
The continuum of HIV care in Catalonia.
Campbell CN, Ambrosioni J, Miro JM, Esteve A, Casabona J, Navarro G, García I, Ferrer E, Force L, Tural C. Campbell CN, et al. Among authors: ambrosioni j. AIDS Care. 2015;27(12):1449-54. doi: 10.1080/09540121.2015.1109584. Epub 2015 Nov 25. AIDS Care. 2015. PMID: 26605781
Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells.
Bermejo M, López-Huertas MR, García-Pérez J, Climent N, Descours B, Ambrosioni J, Mateos E, Rodríguez-Mora S, Rus-Bercial L, Benkirane M, Miró JM, Plana M, Alcamí J, Coiras M. Bermejo M, et al. Among authors: ambrosioni j. Biochem Pharmacol. 2016 Apr 15;106:30-45. doi: 10.1016/j.bcp.2016.02.002. Epub 2016 Feb 4. Biochem Pharmacol. 2016. PMID: 26851491
199 results